- Home
- RAND vs UNCY Comparison
RAND vs UNCY Comparison
Compare RAND & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- UNCY
- Stock Information
- Founded
- RAND 1969
- UNCY 2016
- Country
- RAND United States
- UNCY United States
- Employees
- RAND N/A
- UNCY N/A
- Industry
- RAND Finance: Consumer Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- UNCY Health Care
- Exchange
- RAND Nasdaq
- UNCY Nasdaq
- Market Cap
- RAND 54.4M
- UNCY 74.2M
- IPO Year
- RAND N/A
- UNCY 2021
- Fundamental
- Price
- RAND $16.13
- UNCY $4.10
- Analyst Decision
- RAND
- UNCY Strong Buy
- Analyst Count
- RAND 0
- UNCY 4
- Target Price
- RAND N/A
- UNCY $63.75
- AVG Volume (30 Days)
- RAND 5.0K
- UNCY 476.0K
- Earning Date
- RAND 08-04-2025
- UNCY 08-14-2025
- Dividend Yield
- RAND 10.35%
- UNCY N/A
- EPS Growth
- RAND N/A
- UNCY N/A
- EPS
- RAND N/A
- UNCY N/A
- Revenue
- RAND $7,966,118.00
- UNCY N/A
- Revenue This Year
- RAND N/A
- UNCY N/A
- Revenue Next Year
- RAND N/A
- UNCY $3,131.28
- P/E Ratio
- RAND N/A
- UNCY N/A
- Revenue Growth
- RAND 1.16
- UNCY N/A
- 52 Week Low
- RAND $13.82
- UNCY $2.83
- 52 Week High
- RAND $31.89
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- RAND 46.94
- UNCY 43.94
- Support Level
- RAND $15.17
- UNCY $4.15
- Resistance Level
- RAND $16.20
- UNCY $4.40
- Average True Range (ATR)
- RAND 0.91
- UNCY 0.28
- MACD
- RAND 0.06
- UNCY 0.04
- Stochastic Oscillator
- RAND 71.52
- UNCY 30.30
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.